A PHASE 1, OPEN-LABEL, FIXED-SEQUENCE STUDY TO EVALUATE THE PHARMACOKINETIC INTERACTIONS BETWEEN PF-07976016 AND PF-06882961 IN OTHERWISE HEALTHY ADULT PARTICIPANTS WITH OVERWEIGHT OR OBESITY

The purpose of this study is to see how two study medicines, PF-07976016 and danuglipron, taken together affect the level of each other in the blood of participants who have overweight or obesity.
The total number of weeks of the study is up to approximately 22 weeks (5.5 months).

Start Date13 Mar 2025

Sponsor / Collaborator

Pfizer Inc.

NCT06541678

/ Active, not recruitingPhase 1

A Phase 1, Open-Label, Fixed-Sequence Study to Evaluate the Effect of Itraconazole and Cyclosporine on the Single-Dose Pharmacokinetics of Danuglipron in Healthy Adult Participants

The purpose of this study is to see how single dose of cyclosporine and multiple doses of itraconazole affect the level of the study medicine danuglipron in the blood of healthy adult participants. The information from this study may inform how danuglipron will be used in the future with medicines like cyclosporine and itraconazole.

Start Date23 Dec 2024

Sponsor / Collaborator

Pfizer Inc.

NCT06567327

/ CompletedPhase 1

A Two-Part Phase 1, Open-Label, Fixed-Sequence Study to Evaluate the Multiple Dose Pharmacokinetics of Danuglipron Following Oral Administration and The Effects of Steady-State Danuglipron on the Pharmacokinetics of Single Oral Dose of Atorvastatin and Rosuvastatin in Otherwise Healthy Adult Participants With Overweight or Obesity

The purpose of this study is to learn the following about the study medicine, danuglipron, after multiple days of dosing in healthy adults who are overweight or obese:
* how the study medicine, danuglipron, is taken up into the blood
* if the study medicine, danuglipron, changes how the body processes other study medicines (Atorvastatin and Rosuvastatin)
* about the safety and tolerability of danuglipron
The study will take place in 4 Cohorts (groups). The total number of weeks of the study is about 23 (about 6 months) for Cohort 1 and 22 weeks (about 5.5 months) for Cohort 2, 21 weeks (about 5 months) for Cohort 3 and 20 weeks (about 5 months) for Cohort 4.

Start Date28 Aug 2024

Sponsor / Collaborator

Pfizer Inc.

100 Clinical Results associated with Danuglipron

100 Translational Medicine associated with Danuglipron

100 Patents (Medical) associated with Danuglipron

Literatures (Medical) associated with Danuglipron

03 May 2025·Journal of biomolecular structure & dynamics

Discovery of non-peptide GLP-1r natural agonists for enhancing coronary safety in type 2 diabetes patients

Article

Author: Iranshahi, Mehrdad ; Azimi, Sabikeh G. ; Sadeghi-Aliabadi, Hojjat ; Hadizadeh, Farzin ; Rajabian, Fatemeh ; Shakour, Neda ; Hoseinpoor, Saeideh

This study explores the computational discovery of non-peptide agonists targeting the Glucagon-Like Peptide-1 Receptor (GLP-1R) to enhance the safety of major coronary outcomes in individuals affected by Type 2 Diabetes. The objective is to identify novel compounds that can activate the GLP-1R pathway without the limitations associated with peptide agonists. Type 2 diabetes mellitus (T2DM) is associated with an increased risk of cardiovascular disease (CVD) and mortality, which is attributed to the accumulation of fat in organs, including the heart. Glucagon-like peptide-1 receptor agonists (GLP-1RAs) are frequently used to manage T2DM and could potentially offer cardiovascular benefits. Therefore, this study examines non-peptide agonists of GLP-1R to improve coronary safety in type 2 diabetes patients. After rigorous assessments, two standout candidates were identified, with natural compound 12 emerging as the most promising. This study represents a notable advancement in enhancing the management of coronary outcomes among individuals with type 2 diabetes. The computational methodology employed successfully pinpointed potential GLP-1R natural agonists, providing optimism for the development of safer and more effective therapeutic interventions. Although computational methodologies have provided crucial insights, realizing the full potential of these compounds requires extensive experimental investigations, crucial in advancing therapeutic strategies for this critical patient population.

10 Apr 2025·JOURNAL OF MEDICINAL CHEMISTRY

Discovery of New Difluorocyclobutyl Derivatives as Effective Glucagon-Like Peptide-1 Receptor Agonists with Reduced hERG Inhibitory Activities

Article

Author: Zhang, Jinzhu ; Wang, Jianghai ; Shao, Shuai ; Zhong, Yongqing ; Wang, Guojian ; Huang, Yun ; Tang, Xinyi ; Ma, Zhongjun ; Ding, Wanjing ; Lou, Jinfang ; Li, Yuanyuan ; Miao, Lei ; Xu, Sicong ; Lei, Shaowei

Danuglipron (PF-06882961), a small-molecule agonist of the glucagon-like peptide-1 receptor (GLP-1R) developed by Pfizer, has shown significant potential to reduce blood glucose levels and weight in patients with type 2 diabetes mellitus. However, it has moderate hERG inhibitory activities (IC₅₀ = 4.3 μM), potentially conferring a risk for cardiac toxicity. Here, we report a new class of difluorocyclobutyl derivatives that can be used to reduce the potential hERG inhibition caused by the piperidine ring of danuglipron. After in vitro and in vivo screening, compound 73 was found to be the most potent GLP-1R agonist, with an EC₅₀ of 0.048 nM. Furthermore, compound 73 showed preferable absorption and excellent β-arrestin pathway selectivity compared with danuglipron. In the glucose tolerance test, compound 73 effectively inhibited elevated blood glucose levels. These results indicate that compound 73 is a promising GLP-1R agonist.

01 Apr 2025·DIABETES OBESITY & METABOLISM

Anti‐diabetic effects of GLP‐1 receptor agonists on obese and overweight patients across diabetes status, administration routes, treatment duration and baseline characteristics: A systematic review

Review

Author: Tan, Benjamin Y. Q. ; Poh, Kian Keong ; Kong, William K. F. ; Wong, Hon Jen ; Lin, Norman H. Y. ; Eng, Pei Chia ; Yeo, Leonard L. L. ; Sia, Ching‐Hui ; Chan, Mark Y. ; Toh, Keith Zhi Xian ; Teo, Yao Hao ; Dalakoti, Mayank ; Yeo, Brian S. Y. ; Teo, Yao Neng

Abstract:

Glucagon‐like peptide‐1 receptor agonists (GLP‐1 RAs) are increasingly used for anti‐obesity indications. However, little is known of the comparative effect of GLP‐1 RAs and their glycemic impact across the different routes of administration, diabetic statuses and durations of prescription. PubMed, EMBASE and CENTRAL were searched from inception to 13 February 2024. Only randomised controlled trials were included in this systematic review and meta‐analysis. Adults aged above 18 years old, who were in the overweight/obesity range, with or without type 2 diabetes mellitus (T2DM) were included. Baseline characteristics and changes in glycated haemoglobin (HbA1c) and fasting plasma glucose (FPG) were obtained. GLP1‐RAs demonstrated an overall reduction in HbA1c of −0.72% (95% confidence interval [CI] −0.79 to −0.65, p < 0.01) and in FPG of −1.00 mmol/L (95% CI −1.16 to −0.84, p < 0.01). HbA1c reduction in pre‐DM patients was −0.44% (95% CI −0.54 to −0.18, p < 0.01). Patients who were followed up for more than a year experienced a smaller reduction of HbA1c. Meta‐regression showed that the GLP‐1 RAs are more efficacious at higher HbA1c and lower body mass index. Overall, GLP‐1 RAs consistently led to a significant reduction in HbA1c at −0.72% and FPG at −1.00 mmol/L. These effects may be equally efficacious in pre‐DM patients with obesity and those at lower BMI. With pre‐DM and obesity being risk factors for metabolic syndrome, these findings may provide newer perspectives in expanding indications for GLP‐1 RA initiation.

News (Medical) associated with Danuglipron

23 Jun 2025

·www.biospace.com

Lilly Takes Victory Lap on Oral Weight Loss Drug as Analysts Spot Safety Crack

iStock, Golden Sikorka While Eli Lilly brushed off concerns about gastrointestinal side effects for oral weight loss candidate orforglipron, analysts from William Blair worried that adverse events are not tapering off as expected. As industry watchers eagerly await Eli Lilly’s third quarter obesity data drop for the oral candidate orforglipron, type 2 diabetes data released at the American Diabetes Association has analysts reading the tea leaves for what to expect. In investor notes over the weekend and on Monday, one firm zeroed in on a signal that suggests adverse events are not tapering off over time as is the case with the GLP-1 drugs that have taken the world by storm. Meanwhile, others dubbed the safety data clean. Orforglipron was featured in a session on next-generation oral weight loss drugs at ADA on Saturday. While much of the data from the Phase III ACHIEVE-1 trial had previously been released , clinical investigators had more to say on liver enzymes and tolerability. The results were simultaneously published in The New England Journal of Medicine . Analysts had been worried about the potential of seeing liver enzyme elevations, which could have suggested damage to the organ. But that was not the case—in fact, liver markers actually decreased from baseline by about two to four points, Jefferies noted. Addressing liver enzymes during an investor event over the weekend, Lilly’s management said the FDA is actually pushing companies to include patients with higher baseline liver enzymes to better match the typical patient population. Patients who had higher levels at the start of the trial did not experience elevations, according to the company. All these patients stayed on the study drug and their enzymes normalized or returned to baseline during the trial. “Overall, orfo has a clean pro detailed events of interest showed no real concerns, and [gastrointestinal] tolerability was deemed fine and numerically lower or in line with the injectables (except for diarrhea),” Jefferies wrote. Truist Securities spoke to key opinion leaders at ADA who still voiced concerns about liver enzymes, because the drug will likely be used for chronic weight management. Truist, however, said the concern is “likely overblown.” Leerink Partners similarly heralded the liver data as “clean.” But William Blair took issue with another part of the safety profile: gastrointestinal adverse events. While the firm believes orforglipron will “change practice in T2D,” obesity is a murkier indication, they contend. At the highest dose, nausea, vomiting and constipation did not appear to taper off as it typically does in patients taking GLP-1 drugs like Novo Nordisk’s semaglutide (marketed for weight loss as Wegovy) and Lilly’s own tirzepatide (Zepbound for weight loss), William Blair noted. “We are concerned by the persistence of both severe and frequent gastrointestinal adverse events beyond the titration period,” William Blair wrote. Truist, however, said the gastrointestinal side effects were mostly mild to moderate and mostly occurred during dose escalation as is typical of GLP-1s. The trial was designed to mitigate the symptoms after they were observed in the earlier Phase II trial. Patients in the orforglipron group discontinued the drug because of gastrointestinal side effects at a rate of 2.2% to 5.7%, depending on the dose arm. Truist said it’s notable that the highest dose had a dropout rate of under 6%, a “strong indication of the tolerability of the drug, in our view.” During a call with investors on Saturday, Lilly executives denied the characterization of diarrhea in the study as “persistent.” Jeff Emmick, senior vice president of product development, said there were geographic variabilities in the study, with higher rates of diarrhea seen in patients in India and China and extremely low rates in Japan. The U.S. was “midrange,” he added. The placebo groups in India and China also had fairly high rates of diarrhea, which Emmick said indicates differences in diet. He compared the gastrointestinal adverse events to that of tirzepatide. “Less than 6% at the highest dose discontinued due to a GI adverse event,” Emmick said. “If it had been such a big problem, [we] would have expected higher rates of discontinuation.” The Phase III ATTAIN trial is set to read out in the third quarter, which will finally give investors a glimpse at the weight loss data for orforglipron. Truist believes the diabetes data, which showed the drug significantly lowered blood sugar, has set up a positive readthrough to the obesity indication. The drug is easier to manufacture and for patients to take given it’s an oral, and they can take it without any food restrictions. Lilly plans to approval of orforglipron in obesity by the end of this year, followed by T2D in 2026. Emmick explained the rationale for filing for the weight management indication first. The FDA requires 24 months of exposure data for T2D, and only 18 for weight management. Therefore, since the trials started in parallel, the weight management data will be ready earlier. Lilly Still Believes in Triple G Lilly also used the ADA fanfare to tout its overall cardiometabolic pipeline during the call. Ken Custer, the newly minted president of cardiometabolic health at Lilly, told investors the company expects patient preference to dictate the future of the obesity market. “We fully expect the obesity market will segment into several logical categories based on things like the patient’s preferred route of administration, maybe less frequent dosing, tolerability, maybe a patient wants greater weight loss, different quality of weight loss,” Custer said. Besides weight management and diabetes, Lilly is also testing orforglipron in sleep apnea, similar to what was done with Zepbound. That drug earned a sleep apnea nod from the FDA in December 2024 . Lilly is also testing orforglipron for hypertension as well as examining maintenance dosing with the drug, including switching to the drug after injectables. One asset that caught the eye of BMO Capital Markets is the oral GLP-1 called naperiglipron, a triple G agonist that Lilly has said could unlock higher efficacy, according to BMO. But it uses the same “scaffold” as danuglipron, the failed obesity asset that Pfizer removed from its pipeline in April due to a case of drug-induced liver injury. BMO said Lilly’s continued interest shows the company’s “remaining belief in its potential.” “While history for the scaffold has been challenging, we are interested to learn more why Lilly believes it can evade these past pitfalls,” BMO wrote. If successful, naperiglipron could bring better efficacy in the oral class.

Phase 2Phase 3Clinical Result

21 Jun 2025

·firstwordpharma.com

ADA25: Lilly's oral GLP-1 dodges side effect minefield that sunk Pfizer drug

Eli Lilly detailed safety results for its oral GLP-1 asset orforglipron at the American Diabetes Association (ADA) meeting Saturday, highlighting the absence of liver toxicity, a problem that forced Pfizer to abandon its rival pill earlier this year."This convenient once-daily pill with no restrictions on food and water intake could be an option for millions of people with type 2 diabetes who prefer oral medications over injectables," said Jeff Emmick, Lilly's head of product development. "The positive ACHIEVE-1 results position orforglipron as a potential treatment option with meaningful A1C and weight reduction, and a safety profile similar to injectable GLP-1 therapies."The Phase III study is evaluating once-daily doses of orforglipron (3 mg, 12 mg, and 36 mg) as monotherapy in 559 adults with type 2 diabetes who have not achieved adequate glycaemic control through diet and exercise alone. Toplined earlier this year, patients taking orforglipron saw average reductions in HbA1c between 1.3% and 1.6% after 40 weeks, compared to just 0.1% for those on placebo, meeting the primary endpoint.On the key secondary endpoint of weight loss, patients receiving the 36-mg dose shed an average of 16 pounds, or up to 7.9% of their body weight. Lilly noted that weight loss did not appear to have plateaued by week 40, indicating the possibility for more reductions over time.Cardiometabolic gains"Beyond glycaemic control and bodyweight reduction, we observed reductions in cardiometabolic risk factors, including lipid levels, waist circumference, and systolic blood pressure, findings that indicate a favourable cardiovascular risk profile," researchers wrote in an NEJM paper, which was published Saturday.However, safety remains a central focus, with discontinuation rates and overall tolerability likely to serve as key measures for a therapy meant to be an option for chronic dosing.Lilly reiterated Saturday that orforglipron's overall safety profile in ACHIEVE-1 was consistent with the GLP-1 class as a whole, with gastrointestinal (GI) side effects such as diarrhoea (occurring in 19% to 26% of patients), nausea (13% to 18%), and dyspepsia (11% to 20%) being the most common. The events were generally mild-to-moderate and occurred mainly during dose escalation, researchers wrote.Gradual dosing escalationTo help minimise GI side effects seen in earlier studies, Lilly opted for a gradual dose-escalation strategy, starting with a lower dose and increasing every four weeks.Discontinuation rates due to side effects ranged from 4.4% to 7.8% across orforglipron doses, compared to 1.4% with placebo, and no cases of severe hypoglycaemia or liver safety concerns were reported. The incidence of elevated liver enzymes – three times the upper limit of normal or higher – was similar across all trial groups. In all orforglipron-treated participants, these levels returned to normal or near baseline while they were still receiving the drug, researchers wrote.Pfizer's withdrawal of danuglipron in April due to liver safety concerns had cast a shadow over the entire class of oral small-molecule GLP-1 agonists.Obesity results in Q3Lilly expects to report topline results from ACHIEVE-2, comparing orforglipron to AstraZeneca's SGLT2 inhibitor Farxiga (dapagliflozin), and ACHIEVE-3, comparing it to Novo Nordisk's oral semaglutide, later this year. The company also plans to share results from ATTAIN-1 and ATTAIN-2, evaluating orforglipron for weight management, in the third quarter.

Phase 3Clinical Result

30 Apr 2025

·pharma.economictimes.indiatimes.com

Pfizer leans on cost cuts to offset falling revenue

Bengaluru: Pfizer said on Tuesday it would generate $1.7 billion more in savings from cost cuts to its manufacturing and research operations, highlighting its operational efficiency even as it reported lower first-quarter revenue due to declining sales of its COVID-19 treatment Paxlovid. Chief Executive Albert Bourla, speaking on a conference call with investors, said the drugmaker's story over the next three years would not be one of strong revenue growth, given looming patent expirations on top products, but rather one of earnings growth. The company reaffirmed its full-year forecast, and shares were up nearly 4 per cent. Pfizer also said it had measures in place to mitigate the impact of potential tariffs on pharmaceuticals by the Trump administration, including possibly shifting some production to existing facilities in the United States. "We have huge manufacturing capacity right now in the U.S., particularly for everything that is injectable," Bourla said. "If there is a need, it's clearly there, and without the need to build new facilities." Pfizer has 10 manufacturing sites and two distribution centers in the United States, employing nearly 10,000 people. While the rates and timing of tariffs on the pharma sector are unclear, analysts expect that companies will have to absorb any near-term costs if they are imposed. Washington has launched an investigation into the industry, laying the groundwork for possible levies. Bourla in an interview said the industry is hoping the Trump administration will focus more on medicines like those the World Health Organization has designated as essential, which tend to be off-patent and produced mostly in China and India. "I think that's where the problem is. It's not if an obesity drug is made in Ireland," he said. LEANING ON COST SAVINGS The company said it now expects about $7.7 billion in savings by the end of 2027 from its cost-cutting programs. That includes an additional $500 million in R&D savings, which at least two investors said could reflect Pfizer's recent decision to stop development of its experimental weight-loss pill danuglipron. "The cost savings are real, it does help drive better bottom line performance," said Brian Mulberry, portfolio manager at Zacks Investment Management, which owned 2.44 million Pfizer shares at the end of 2024. "We just want to know where that top-line growth is going to come from." Not from COVID antiviral Paxlovid, apparently. Sales of the two-drug treatment were $491 million, well short of analysts' already diminished expectations of $794.3 million, according to LSEG data. Analysts significantly cut their Paxlovid sales expectations in recent weeks due to a relatively small winter wave of COVID-19 in the U.S. On an adjusted basis, Pfizer earned 92 cents per share in the first quarter, topping analysts' expectations by 26 cents, helped by cost cuts and a lower tax rate. Despite the earnings beat, Pfizer is still forecasting a full-year adjusted profit of $2.80 to $3.00 per share on revenue of $61 billion to $64 billion. CFO David Denton said Pfizer was "currently trending toward the upper end" of its profit forecast. Revenue in the quarter fell 8 per cent from a year ago to $13.72 billion and missed analysts' expectations of $13.91 billion. Potential tariffs could add to existing pressure for Pfizer. Investors have been pushing the company to bring new drugs to market that could make up for revenue likely to be lost from some top-selling medicines nearing the end of patent protection. Zacks' Mulberry said the company has done well at becoming more productive on the manufacturing side. "That's where they're finding a bulk of the savings at this point," he said, "but I don't see the next kind of really big pop in revenue." Even the drugs that outperformed Wall Street expectations in the first quarter face headwinds. Sales of its heart disease drug, sold under the brand names Vyndaqel and Vyndamax, were $1.49 billion, above estimates of $1.29 billion. But the company said it is already seeing the impact of new competition, which it expects to continue through the year. Pfizer's vaccine business could also face greater regulatory scrutiny under the new Health Secretary Robert F. Kennedy Jr., a longtime vaccine skeptic. COVID vaccine Comirnaty, which Pfizer makes with German partner BioNTech, brought in sales of $565 million. Analysts were expecting $331.7 million for the shot in the first quarter. (Reporting by Bhanvi Satija and Christy Santhosh in Bengaluru and Michael Erman in New York; Editing by Anil D'Silva and Bill Berkrot)

Vaccine

100 Deals associated with Danuglipron

External Link

KEGG	Wiki	ATC	Drug Bank
D11910	-	-	DB16043

R&D Status

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Obesity	Phase 2	United States	Pfizer Inc.	06 Jan 2021
Diabetes Mellitus, Type 2	Phase 2	United States	Pfizer Inc.	15 Oct 2019
Diabetes Mellitus, Type 2	Phase 2	Bulgaria	Pfizer Inc.	15 Oct 2019
Diabetes Mellitus, Type 2	Phase 2	Canada	Pfizer Inc.	15 Oct 2019
Diabetes Mellitus, Type 2	Phase 2	Hungary	Pfizer Inc.	15 Oct 2019
Diabetes Mellitus, Type 2	Phase 2	Poland	Pfizer Inc.	15 Oct 2019
Diabetes Mellitus, Type 2	Phase 2	Slovakia	Pfizer Inc.	15 Oct 2019
Diabetes Mellitus, Type 2	Phase 2	South Korea	Pfizer Inc.	15 Oct 2019
Diabetes Mellitus, Type 2	Phase 2	Taiwan Province	Pfizer Inc.	15 Oct 2019
Liver Injury	Phase 1	United States	Pfizer Inc.	30 Dec 2020

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT04889157 (CTgov)	Phase 1	Diabetes Mellitus, Type 2	20	Placebo	svbxuggpxa = vchcgslcic uvlxgxifxa (ihnmhndylm, kygihzxkzr - omfqirehsa) View more	-	01 Oct 2024
NCT04616027 (CTgov)	Phase 1	Diabetes Mellitus, Type 2	42	PF-06882961 (Healthy and Normal Renal Function)	pxwjnisxer(wtbamsveeh) = cpbyjamass iydltnupzk (rjpkldxbns, 28) View more	-	10 May 2024
				PF-06882961 (T2DM Normal Renal Function)	pxwjnisxer(wtbamsveeh) = araxjqgdhz iydltnupzk (rjpkldxbns, 58) View more
NCT04604496 (CTgov)	Phase 1	Liver Injury	24	PF-06882961 (Without Hepatic Impairment)	byiisfdgxb(euwsznolqr) = cistysbfof fpxkngyoar (rzuktsjemj, 50) View more	-	21 Mar 2024
				PF-06882961 (Mild Hepatic Impairment)	byiisfdgxb(euwsznolqr) = zjymykxfwd fpxkngyoar (rzuktsjemj, 33) View more
NCT04707313 (Corporate Publications) Manual	Phase 2	Obesity	-	Danuglipron	nywqkiclno(pgqjathtld) = mpsqgvwmod gvwudvsmbw (xnilzxvuvv ) View more	Negative	01 Dec 2023
				Placebo	nywqkiclno(pgqjathtld) = lnelcwvwus gvwudvsmbw (xnilzxvuvv ) View more
NCT04621227 (CTgov)	Phase 1	Obesity	16	Rosuvastatin (Rosuvastatin 10mg (Period 1))	ynhgkjzrie(uxcxygzewh) = wdmioiqexv jlqhspvagf (mnsevdfcws, 43) View more	-	01 Dec 2023
				Rosuvastatin+PF-06882961 (PF-06882961 120mg BID + Rosuvastatin 10mg (Period 4))	ynhgkjzrie(uxcxygzewh) = tysycpsgpv jlqhspvagf (mnsevdfcws, 50) View more
NCT04617275 (Pubmed)	Phase 2	Diabetes Mellitus, Type 2	151	Placebo	dhzizpplfi(hkxtwnqqzv) = iqtlhxwelp gkumbkhmfu (rbiubbyard ) View more	-	13 Jun 2023
				Danuglipron low starting dose (5-mg)	dhzizpplfi(hkxtwnqqzv) = xqfjlnqzng gkumbkhmfu (rbiubbyard ) View more
NCT03985293 (Literature) Manual	Phase 2	Diabetes Mellitus, Type 2	411	Danuglipron 2.5 mg	oyevzbiyqa(lxwfdweuld) = nkrbjpkydm qolnztdirw (vqhgghtbif, -0.70 to to 0.28) View more	Positive	22 May 2023
				Danuglipron 10 mg	oyevzbiyqa(lxwfdweuld) = aoibardmho qolnztdirw (vqhgghtbif, -1.11 to to 0.72) View more
NCT03985293 (Pubmed)	Phase 2	Diabetes Mellitus, Type 2	411	Danuglipron 2.5 mg	cxqsdqemig(oflhujqige) = qkpxpzxnvy ialcobaddp (rbhjrjcomt, -1.47 to -0.86) View more	Positive	01 May 2023
				Danuglipron 80 mg	faymkseirg(oxmzbaivbo) = dbmvcxstek pciwsgxuaj (jocdlmbpph, -3.01 to -1.07)
NCT04617275 (CTgov)	Phase 2	Diabetes Mellitus, Type 2 \| Obesity	151	Placebo (Placebo (T2DM))	rbeuncxnbo = jzjmhrafmi gtmufggsrx (gthlhpumwe, usjzxjvagh - ookvwtpahb) View more	-	08 Dec 2022
				PF-06882961 (PF-06882961 80 mg BID Low, Slow (T2DM))	rbeuncxnbo = zyofcwkpbq gtmufggsrx (gthlhpumwe, jexscccihs - hxnssidtpb) View more
NCT04552470 (Pubmed) Manual	Phase 1	Diabetes Mellitus, Type 2	37	danuglipron	wzcudtxvck(hmsksxkhwa) = Most treatment-emergent adverse events were of mild or moderate intensity. anifhugzdt (cqyhpbkgvi )	Positive	26 Nov 2022
				Placebo

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

AI Agents Built for Biopharma Breakthroughs

Accelerate discovery. Empower decisions. Transform outcomes.

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis